Health Condition 1: K20-K31- Diseases of esophagus, stomach and duodenum
Conditions
Interventions
Intervention1: Nil: Nil
Control Intervention1: Nil: Nil
Sponsors
Mankind Pharma Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Medical records of adult patients equal or above 18 years of age with symptoms of reflux esophagitis and treated with vonoprazan 20 mg once daily as per local prescribing guidelines will be retrieved and screened for further analysis.
Exclusion criteria
Exclusion criteria: Screened records will not be considered for evaluation if patients had esophageal comorbidities, prior gastrointestinal or esophageal surgery, recent use of acid-suppressing therapy, H. pylori eradication within 28 days, significant hepatic dysfunction, inflammatory bowel disease, malignancy, or hypersensitivity to vonoprazan.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effectiveness will be evaluated as treatment response based on mean improvement in the FSSG questionnaire score and heart burn resolutionTimepoint: From baseline till 2 weeks and 4 weeks after treatment initiation | — |
Secondary
| Measure | Time frame |
|---|---|
| Physician Global Assessment (PhGA) Scale for treatment response, as well as safety and tolerability evaluated through recorded adverse drug reactions.Timepoint: From baseline till 2 weeks and 4 weeks after treatment initiation | — |
Countries
India
Contacts
Public ContactDr Darshan Rana MBBS MD
Mankind Pharma Ltd
Outcome results
None listed